Syntara (SNT) Stock Price, News & Analysis

Company Overview

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Electronic Equipment
• Current Symbol: ASX:SNT
• CIK: N/A
• Web: www.syntaratx.com.au
• Phone: 61-2-9454-7200
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$13.67 million
• Net Margins: -262.70%
• Pretax Margin: N/A
• Return on Equity: -191.95%
• Return on Assets: -49.87%

Debt

• Debt-to-Equity Ratio: 5.15
• Current Ratio: 1.79
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: A$5.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,370,000,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: 0.62